ENTO: כמות מזומנים למניה Entero Therapeutics Inc.

Entero Therapeutics, Inc. (ENTO) develops enzyme-based treatments to combat toxins associated with celiac disease. As the company is currently in the testing phase and lacks profitability, its development is supported by external financing. The cash per share metric demonstrates liquidity, where the level of 0.75 represents the current value. Such innovations enable intestinal recovery in cases where conventional diets prove ineffective.
פילוחים אנליטיים של חברת Entero Therapeutics, Inc.

This metric reveals real liquidity through the ratio of total cash balances to the number of shares outstanding. The metric determines the amount of actual capital per share, excluding illiquid assets. For Entero Therapeutics, Inc. (ENTO), with its compact team of researchers, this is a critical indicator of the ability to fund clinical phases and patenting. By analyzing the change in cash per share, an investor assesses the sustainability of the company's cash cushion.